Xarelto Multidistrict Litigation

On October 4, 2016, the Judicial Panel on Multidistrict Litigation ordered the formation of MDL No. 2740 and transferred 33 federal court actions to the Eastern District of Louisiana for coordinated proceedings. Judge Jane Triche Milazzo has been assigned as the transferee judge to oversee this MDL, entitled "In re: Taxotere (Docetaxel) Products Liability Litigation." Judge Milazzo was appointed to the EDLA bench in 2011 by President Obama.

Taxotere (docetaxel) is a chemotherapy drug, which has been marketed by its innovator Sanofi-Aventis and subsequent 505(b)(2) manufacturers as an alternative to Taxol (paclitaxel) and other early-stage cancer treatment options. Until December 2015, the drug carried no express warning of permanent or irreversible hair loss.

Nonetheless, the manufacturers have known that administration of Taxotere (docetaxel) carries a risk of irreversible alopecia. Indeed, there have been many reports of permanent baldness in cases where Taxotere is used. Plaintiffs in this litigation, therefore, claim that docetaxel was defective because they (and their doctors) were not warned of the common risk of persistent, irreversible hair loss . Plaintiffs further claim that the manufacturers withheld information from the public and the medical community and failed to adequately warn of this important risk to early stage cancer patients.

Our firm has extensive experience in complex cases involving mass actions or claims against drug manufacturers; and we have handled such claims, with success, in this same court. Because of this track record, we are familiar with the processes by which this Taxotere case will be handled, and we are confident in our ability to achieve a just outcome for patients and their families.

If you or a loved one has suffered injury as a result of Taxotere (docetaxel), please contact our firm for an evaluation at 504-522-2304.